HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells.

Abstract
Tumors of the nervous system, including neuroblastoma and glioblastoma, are difficult to treat with current therapies. Despite the advances in cancer therapeutics, the outcomes in these patients remain poor and, therefore, new modalities are required. Recent literature demonstrates that cytotoxic effector cells can effectively kill tumors of the nervous system. In addition, we have previously shown that umbilical cord blood (UCB) contains precursors of antitumor cytotoxic effector cells. Therefore, to evaluate the antitumor potential of UCB-derived effector cells, studies were designed to compare the in vitro and in vivo antitumor effects of UCB- and peripheral blood (PB)-derived antigen-nonspecific and antigen-specific effector cells against tumors of the nervous system. Mononuclear cells (MNCs) from UCB were used to generate both interleukin-2 (IL-2)-activated killer (LAK) cells and tumor-specific cytotoxic T lymphocytes (CTLs). UCB-derived LAK cells showed a significant in vitro cytotoxicity against IMR-32, SK-NMC, and U-87 human neuroblastoma and glioblastoma, respectively. In addition, the CTLs generated using dendritic cells primed with IMR-32 tumor cell lysate showed a selective cytotoxicity in vitro against IMR-32 cells, but not against U-87 or MDA-231 cells. Furthermore, treatment of SCID mice bearing IMR-32 neuroblastoma with tumor-specific CTLs resulted in a significant (p < 0.01) inhibition of tumor growth and increased overall survival. Thus, these results demonstrate the potential of UCB-derived effector cells against human neuroblastoma and warrant further preclinical studies.
AuthorsAvadhut D Joshi, Erin M Clark, Peng Wang, Corey M Munger, Ganapati V Hegde, Sam Sanderson, Harish P G Dave, Shantaram S Joshi
JournalJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology (J Neuroimmune Pharmacol) Vol. 2 Issue 2 Pg. 202-12 (Jun 2007) ISSN: 1557-1904 [Electronic] United States
PMID18040845 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Topics
  • Animals
  • Cell Line, Tumor
  • Cells, Cultured
  • Cytotoxicity, Immunologic (immunology)
  • Fetal Blood (cytology, immunology, transplantation)
  • Glioblastoma (immunology, therapy)
  • Humans
  • Immunotherapy (methods)
  • Killer Cells, Lymphokine-Activated (immunology, transplantation)
  • Leukocytes, Mononuclear (immunology, transplantation)
  • Mice
  • Mice, SCID
  • Neuroblastoma (immunology, therapy)
  • T-Lymphocytes, Cytotoxic (immunology, transplantation)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: